This paper reviews briefly the most relevant indications for ABMT in Hodgkin's disease. The accurate definition of prognostic categories at the time of first treatment failure and the role of ABMT in the early sequential treatment of highly effective drug combination followed by high dose chemotherapy in very high risk Hodgkin's disease patients, are also discussed.